35th Annual Meeting of the European Group for Blood and Marrow Transplantation
25th Meeting of the EBMT Nurses Group
8th Meeting of the EBMT Data Management Group
3rd Patient & Family Day
Göteborg, Sweden
29.03.2009 - 01.04.2009

Please select a day:

Personal programme

Please enter your email address here in order to bring up your personal programme

Home - 31.03.2009

Tuesday, March 31, 2009
17:30 - 19:00

Physicians Poster Session

Infectious complications

		Impairment of anti-leukaemia and anti-tumour CD8+ cytotoxic T-lymphocyte function by antifungal agents in vitro	P 825
		E. Distler, H.H. Chapin, E. Koch, C. Lass-Flörl, A. Ullmann, C. Huber, W. Herr (Mainz, DE; Innsbruck, AT)
		Genetic polymorphisms in the genes encoding human Toll-like receptor 1-10	P 826
		C. Enevold, I. Christensen, B. Kornblit, K. Bendtzen, C. Heilmann, N. Jacobsen, K. Müller (Copenhagen, DK)
		Prospective evaluation of Candida mannan and mannan antibody to diagnose candidiasis in febrile neutropenic patients	P 827
		M. Ellis, B. Al-Ramadi, R. Bernsen, J. Kristensen, H. Alizadeh, U. Hedstrom (Al Ain, AE)
		Neglected tropical diseases in haematopoietic stem cell transplantation: a single-centre experience in Brazil	P 828
		T.C. Martins, I. Colturato, M. S. Leite, A.J. Simione, V. Colturato, M.P. de Souza, M. Mauad, W. Azevedo, C.M. Machado (Jaú, São Paulo, BR)
		Each herpesvirus elicits a unique T-cell response in chronically infected healthy individuals	P 829
		F. Khan, S. Sy, S. Liu, F. Zhou, Y. Liu, A. Ugarte-Torres, J. Storek (Calgary, CA)
		The impact of Dectin-1 polymorphism Tyr238Stop on the occurrence of Candida colonisation and disease of haematopoietic stem cell transplantation recipients	P 830
		W.J.F.M. van der Velden, T.S. Plantinga, B. Ferwerda, P. Donnelly, M.G. Netea, N.M.A. Blijlevens (Nijmegen, NL)
		The natural history and control of cytomegalovirus infection following allogeneic stem cell transplantation	P 831
		G. Garnett, M. Boeckh, H. Einsele, V. Emery (London, UK; Seattle, US; Würzburg, DE)
		Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis following a reduced-intensity allogeneic haematopoietic stem cell transplantation	P 832
		R. Martino, R. Parody, J.L. Piñana, D. Valcarcel, A. Sureda, S. Brunet, J. Briones, J. Delgado, F. Sanchez, N. Rabella, J. Sierra (Barcelona, ES)
		Outbreak of waterborne Pseudomonas aeruginosa infections in a reverse isolation haematology unit	P 833
		A.F. Widmer, R. Frei, M. Stern, D. Heim, C. Arber, M. Battegay, U. Flückiger, A. Gratwohl (Basel, CH)
		Children with acute leukaemia have an increased risk for Varicella zoster reactivation after allogeneic stem cell transplantation: a possible role for fludarabine	P 834
		A.C. Lankester, C.M.. Jol-van der Zijde, P. Hissinkmuller, A.C.T.M. Vossen, L.M. Ball (Leiden, NL)
		Different CMV and EBV reactivation among alternative donor transplants depending on the type of stem cell source: a single-centre analysis	P 835
		M. Mikulska, A. Ibatici, A. Dominietto, A.M. Raiola, V. Pinto, M. Soracco, F. Gualandi, V. Del Bono, T. Lamparelli, M.T. Van Lint, C. Viscoli, A. Bacigalupo, F. Frassoni (Genoa, IT)
		Reappraisal of bacterial prophylaxis in allogeneic marrow or peripheral blood stem cell transplantations after myeloablative conditionings	P 836
		J. Kanda, T. Ichinohe, T. Saito, K. Yamashita, T. Kondo, T. Ishikawa, S. Ichiyama, T. Uchiyama (Kyoto, JP)
		Functional immune reconstitution after high-dose chemotherapy parallels control of endogenous viral reactivation: the torquetenovirus model	P 837
		D. Focosi, F. Maggi, M. Albani, J. Rocchi, V. Ricci, S. Gragnani, M. Ghimenti, F. Papineschi, M. Bendinelli, M. Pistello, L. Ceccherini-Nelli, M. Petrini (Pisa, IT)
		Risk of hepatitis B development and efficacy of prophylaxes with lamivudine after allogeneic stem cell transplantation	P 838
		L. Giaccone, I. Resta, A. Marengo, R. Sorasio, F. Fiore, M. Rizzetto, M. Boccadoro, A. Marzano, B. Bruno (Turin, IT)
		Posaconazole and cyclosporine drug interaction in allogeneic HSCT: dose adjustment, interaction kinetics and safety profile	P 839
		I. Sánchez-Ortega, T. Caballero, C. Montes, B. Patiño, J. Villa, M. Arnan, L. Yáñez, A. Iriondo, L. Vázquez, R.F. Duarte (Barcelona, Salamanca, Santander, ES)
		Tetramer-screening to predict the risk of recurrent CMV-reactivation after HSCT: a 2-year screening and follow-up phase	P 840
		S. Borchers, S. Luther, N. Hahn, J. Kontsendorn, M. Stadler, H. Diedrich, A. Ganser, E.M. Weissinger (Hannover, DE)
		Respiratory syncytial virus infection in recipients of allogeneic stem cell transplantation: retrospective study of the incidence, clinical features and outcome	P 841
		G. Avetisyan, J. Mattsson, P. Ljungman (Stockholm, SE)
		CMV infection and disease after allogeneic stem cell transplantation with reduced-intensity conditioning	P 842
		G. Avetisyan, H. Hägglund, Z. Hassan, K. LeBlanc, J. Mattsson, O. Ringdén, J. Winiarski, P. Ljungman (Stockholm, SE)
		RSV infection after allogeneic haematopoietic stem cell transplantation from a single centre	P 843
		F. Piazera, S. Fortier, J. Morando, C. Bonfim, M. Bitencourt, V. Funke, D. Setubal, J. Ruiz, C. Arns, R. Silva, R. Pasquini, C. Medeiros, J. Zanis-Neto (Curitiba, BR)
		Voriconazole plasma levels monitoring in allogeneic haematopoietic stem cell transplant recipients	P 844
		J. Winterová, Z. Rácil, L. Malášková, I. Kocmanová, B. Weinbergerová, J. Mayer (Brno, CZ)
		Prevalence of multiresistant pathogens in surveillance and clinical isolates from patients undergoing haematopoietic stem cell transplantation in Hungary: a single-centre experience	P 845
		C. Kassa, J. Sinkó, K. Kállay, A. Kertész, M. Konkoly-Thege, G. Kriván (Budapest, HU)
		Incidence of Clostridium difficile infection in patients undergoing allogeneic stem cell transplantation – A single-centre analysis	P 846
		G. Beutel, S. Buchholz, J. Krauter, E. Dammann, H. Diedrich, M. Stadler, P. Kirschner, A. Ganser, M. Eder (Hannover, DE)
		Multiple co-pathogens are associated with increased morbidity and mortality in parainfluenza virus 3 infection	P 847
		A. Hodson, M. Kasliwal, A Retter, K. Cuthill, M. Streetly, M. Kazmi, E. MacMahon, K. Raj (London, UK)
		Refractory late onset haemorrhagic cystitis following fludarabine and alemtuzumab conditioned allogeneic haematopoietic stem cell transplant	P 848
		A. Hodson, M. Streetly, P. Fields, K. Raj, E. MacMahon, M. Kazmi (London, UK)
		Immune response of human polymorphonuclear neutrophils to Aspergillus fumigatus	P 849
		J. Loeffler, M. Mezger, I. Wozniok, H. Einsele (Würzburg, DE)
		The rate of cytomegalovirus infection and disease in correlation with the type of haematopoietic stem cell transplantation in the era of pre-emptive antiviral therapy	P 850
		B. Gesundheit, R. Or, E. Budowski, M. Shapira, I. Resnick, S. Samuel, L. Dray, O. Kaplan , D. Wolf (Jerusalem, IL)
		Neutropenic enterocolitis: usefulness of ultrasound sonography. Single-centre experience	P 851
		E. Benedetti, F. Simonetti, F. Caracciolo, F. Papineschi, E. Orsitto, M. Tonerini, B. Bruno, M. Pelosini, D. Focosi, M. Petrini (Pisa, Turin, IT)
		Outcome of allogeneic haematopoietic stem cell transplantations in patients with secondary antifungal prophylaxis due to proven or suspected prior fungal infection	P 852
		S. Rohde, M. Leithäuser, G. Kundt, M. Haversath, D. Wolff, I. Hilgendorf, H. Andree, J. Casper, C. Kahl, M. Freund, C. Junghanss (Rostock, DE)
		Cytomegalovirus pre-emptive strategy guided by Ag pp65 or quantitative PCR after reduced-intensity conditioning allogeneic stem cell transplantation: a single-centre experience	P 853
		J.L. Piñana, R. Martino, N. Rabella, P. Barba, N. Margall, M. Roig, D. Valcarcel, J. Sierra (Barcelona, ES)
		Adoptive transfer of cytomegalovirus-specific CD8+ T-cells powered by streptamer technology leads to enduring virus clearance in patients after allogeneic stem cell transplantation	P 854
		A. Schmitt, T. Tonn, D. Busch, G. Grigoleit, H. Einsele, M. Odenthal, L. Germeroth, M. Ringhoffer, S. Ringhoffer, M. Wiesneth, D. Michel, T. Mertens, M. Rojewski, M. Marx, S. von Harsdorf, H. Döhner, E. Seifried, D. Bunjes, M. Schmitt (Rostock, Frankfurt, Munich, Würzburg, Göttingen, Ulm, DE)
		NOD2/CARD15 polymorphism evaluation in autologous stem cell transplantation	P 855
		S. Giammarco, S. Bellesi, P. Chiusolo, S. Marietti, D. De Ritis, L. De Padua, E. Metafuni, G. Leone, S. Sica (Rome, IT)
		Prospective study of oral valganciclovir for pre-emptive therapy of cytomegalovirus after allogeneic stem cell transplantation	P 856
		R. de la Camara, L. Vazquez, J. Lopez, C. Solano, D. Serrano, A. Garcia Noblejas, J.M. Ribera Santasusana, C. Ferra (Madrid, Salamanca, Valencia, Barcelona, ES)
		Towards standardisation of Epstein-Barr viral load quantification: comparison of four different ways of measurement in peripheral blood of paediatric patients after allogeneic haematopoietic stem cell transplantation	P 857
		S. Volke, B. Gruhn, W. Woesmann, E. Landmann, J. Beck, A. Reiter, H. Wagner (Giessen, Jena, DE)
		Use of saliva in the detection of HCMV DNA in allogeneic stem cell transplantation and its comparison with viral load in blood by real-time PCR	P 858
		J. Correa-Silva, O. Bruna-Romero, R. Resende, L. Miranda, F. Oliveira, F. Costa, S. Xavier, S. Figueiredo-Neves, R. Gomez, H. Bittencourt (Belo Horizonte, BR)
		EBV and HHV-6 reactivation associate with mental disturbances in alloHSCT patients	P 859
		A. Burniak, E. Jaskula, S. Madej, A. Lange (Wroclaw, PL)
		Reactivations of CMV, HHV6 and EBV differ with respect to the risk factors and the clinical outcome in patients post haematopoietic stem cell transplantation	P 860
		E. Jaskula, D. Dlubek, A. Tarnowska, D. Duda, A. Lange (Wroclaw, PL)
		Levofloxacin prophylaxis after high-dose chemotherapy and autologous peripheral stem cell support: does it work? A single-centre experience	P 861
		A. Anastasia, L. Castagna, S. Bramanti, B. Sarina, R. Mazza, E. Todisco, L. Giordano, A. Santoro (Rozzano, IT)
		Impact of prior invasive pulmonary aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation	P 862
		J. El-cheikh, L. Wang, C. Faucher, S. Furst, B. Esterni, P. Berger, D. Blaise (Marseille, FR)
		Use of “high flow” totally implantable central venous access ports for myeloablative conditioning followed by allogeneic stem cell transplantation: a prospective study	P 863
		A. Abdelkefi, O. Ben Gaied, S. Laabidi, H. Allouche, S. Ladeb, N. Ajmi, M. Maamar, L. Torjeman, A. Lakhal, A. Mezlini, M. Elloumi, N. Ben Romdhane, T. Ben Othman (Tunis, Sfax, TN)
		Graft-versus-host disease and fungal infections are the main outcome predictors after allogeneic stem cell transplantation using reduced-intensity conditioning regimens	P 864
		F. Patriarca, M.l. Battista, A. Sperotto, M. Medeot, A. Geromin, M. Cerno, E. Toffoletti, S. Buttignol, C. Savignano, C. Rinaldi, V. Miotti, R. Fanin (Udine, IT)
		Early recovery of immunoglobulin levels at 3 months after allogeneic peripheral blood stem cell transplantation can predict favourable transplantation outcomes	P 865
		J.H. Moon, S.J. Lee, J.G. Kim, Y.S. Chae, S.N. Kim, J.S. Suh, K.S. Lee, S.K. Sohn (Daegu, KR)
		Infectious complications after cord blood transplant: impact on mortality and analysis of risk factors for bacterial, fungal and viral infections	P 866
		C. Girmenia, L. Malandruccolo, A.P. Iori, W. Barberi, G.F. Torelli, V. Valle, E. Iannella, B. Lucarelli, M. Screnci, G. Gentile, A. Micozzi, R. Foà (Rome, IT)
		Serum vascular endothelial growth factor in adult haematological patients with neutropenic fever: a prospective comparison with C-reactive protein	P 867
		E. Jantunen, S. Hämäläinen, I. Matinlauri, T. Kuittinen, I. Koivula, A. Juutilainen (Kuopio, Turku, Helsinki, FI)
		Risk of bacterial contamination at autologous peripheral blood stem cell collection and infusion	P 868
		A. Yilmaz, E. Ayyildiz, M. Bay, A. Azap, G. Gürman, Ö. Arslan, O. Ilhan, M. Arat (Ankara, TR)
		Monitoring strategy of adenovirus infections in allogeneic stem cell transplant patients	P 869
		H. Omar, G. Avetisyan, P. Ljungman (Huddinge, SE)
		No difference in the risk of invasive fungal infections after HLA identical sibling or unrelated donor transplantation receiving low-dose ATG-F in the preparative regimen before transplant. Results from a single centre	P 870
		F. Bonifazi, G. Bandini, S. Usai, E. Colaci, M. Stanzani, M. Arpinati, N. Vianelli, M.R. Motta, S. Rizzi, M. Baccarani (Bologna, IT)
		Cytomegalovirus-specific immune reconstitution monitored by ELISPOT assay in allogeneic haematopoietic stem cell transplantation	P 871
		C. Nozzoli, L. De Risi, S. Guidi, A. Orsi, B. Bartolozzi, A. Gozzini, L. Lombardini, R. Saccardi, A. Bosi (Florence, IT)
		Treatment of respiratory syncytial virus infection with nebulised ribavirin and the humanised monoclonal antibody palivizumab in eight haemopoietic stem cell transplant recipients	P 872
		D.A. Tsitsikas, H. Oakervee, J. Cavenagh, S. Agrawal, J. Gribben, F. Mattes (London, UK)
		Long-term low-dose valacyclovir against Varicella-zoster virus reactivation after allogeneic haematopoietic stem cell transplantation	P 873
		K. Oshima, T. Takahashi, T. Mori, T. Matsuyama, K. Usuki, Y. Asano-Mori, F. Nakahara, S. Okamoto, M. Kurokawa, Y. Kanda (Saitama, Tokyo, Tochigi, JP)
		Low-dose amphotericin B lipid complex or liposomal amphotericin B prophylaxis of invasive fungal infections in children following stem cell transplantation for haemoglobinopathies	P 874
		J. Gaziev, C. Alfieri, M. Marziali, A. Isgro, P. Sodani, P. Polchi, M.D. Simone, C. Gallucci, K. Paciaroni, A. Roveda, G. De Angelis, A. Montuoro, G. Lucarelli (Rome, IT)
		Secondary prophylaxis and pre-emptive antifungal therapy are effective in allogeneic transplanted patients nursed in highly protective environment	P 875
		P. Marenco, G. Grillo, G. Bertani, C. Gabutti, V. Mancini, M. Turrini, A. Brizio, E. Morra (Milan, IT)
		The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-centre experience	P 876
		B.S. Sohn, D.H. Yoon, S. Kim, D.H. Lee, S.W. Kim, J. Huh, J.S. Lee, C. Suh (Seoul, KR)
		Rota- and calicivirus infections following allogeneic haematopoetic stem cell transplantation	P 877
		K. Kállay, J. Sinkó, G. Benyó, Á. Tóth, V. Goda, G. Kriván (Budapest, HU)
		Preliminary monocentric survey on the prevalence of HBV seropositivity in HSCT recipients	P 878
		P. Usardi, C. Annaloro, M. Viganò, P. Lampertico, F. Onida, E. Tagliaferri, A. Della Volpe, G. Lambertenghi Deliliers (Milan, IT)
		Catheter-related infections in tunnelled central venous devices in haematologic malignancies and haematopoietic stem cell transplantation patients. A single-centre experience	P 879
		E. Carrillo Cruz, J. Falantes González, J. González Campos, M. Ruiz Seixas, A. Urbano Ispizua, I. Espigado Tocino (Sevilla, ES)
		High efficacy and low toxicity of short-course oral valganciclovir given as one-week BID treatment and one-week QD maintenance as pre-emptive therapy for post-HSCT CMV infection	P 880
		A.J.M. Saleh, F. Al-Mohareb, F. Al-Rabiah, N. Chaudhri, F. Al-Sharif, H. Al-Zahrani, S. Mohamed, K. Al-Anazi, M. Patel, W. Rasheed, A. Elghazaly, M. Bakr, S. Ahmed, A. Nassar, F. Hussain, Z. Nurgat, H. Al-Abdely, M. Aljurf (Riyadh, SA)
		Peripherally inserted central venous catethers in the management of autologous haematopoietic stem cell transplantation	P 881
		S. Bellesi, G. De Pascale, P. Chiusolo, G. Scoppettuolo, M. Pittiruti, F. Sorà, L. Laurenti, G. Leone, S. Sica (Rome, IT)
		Frequency and mains causes of the febrile episodes during myeloablative chemotherapy neutropenia induced after bone marrow transplant	P 882
		A. Talbi, R. Ahmed Nacer, M. Benakli, R. Belhadj, F. Mehdid, M. Baazizi, N. Rahmoune, K. Saidani, D. Ait Ouali, S. Madene, S. Abderrahmani, R.M. Hamladji (Algiers, DZ)
		Cytomegalovirus DNAemia and treatment following allogeneic stem cell transplantation with focus on long-term outcome	P 883
		J. Lindahl (Göteborg, SE)
		Emergence of uncommon infection in bone marrow transplantation: the modern Trojan horse?	P 884
		T. Zuckerman, N. Benyamini, N. Haddad, R. Fineman, I. Avivi, E. Sabo, J.M. Rowe, I. Oren (Haifa, IL)
		Invasive fungal infection in patients after allogeneic haematopoietic stem cell transplantation. A single-centre experience	P 885
		N. Zubarovskaya , Y. Vasilieva, E. Semenova, N. Stancheva , E. Morozova, N. Klimko, A. Chukhlovin , B. Afanasyev (St. Petersburg, RU)
		The utility of screening swabs in allogeneic haematopoeitic stem cell transplant recipients: a retrospective evaluation	P 886
		S. Ager, N. Young, H. Inns, G. Cook, M. Gilleece, S. Liebersbach, G. Shenton, T. Collyns (Leeds, UK)
		Posaconazole has superior clinical efficacy and cost-effectiveness to itraconazole for antifungal prophylaxis in allogeneic stem cell transplant recipients: a single-centre experience	P 887
		R.F. Duarte, B. Patiño, C. Muñoz, M. Arnan, T. Peralta, C. Gudiol, I. Sánchez-Ortega, R. Parody, A. Clopés, J.L. López-Belmonte, F.J. Sabater, A. Fernández de Sevilla (Barcelona, Madrid, ES)
		Is serological or PCR positivity of Toxoplasma gondii in donor or recipient the reason for haematopoietic stem cell transplantation delay?	P 888
		L. Krol, M. Matulova, P. Hubacek, P. Keslova, R. Formankova, P. Sedlacek (Prague, CZ)
		Ciprofloxacine as an antibacterial prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation – A single-centre experience	P 889
		A. Wolska, A. Wierzbowska, A. Szmigielska-Kaplon, A. Pluta, T. Robak (Lodz, PL)
		Use of ciprofloxacin to prevent bacterial infection in patients receiving high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma, AML, and lymphoma/solid tumours	P 890
		E. Bauernschmitt, T. Szislo, C. Peschel, H. Menzel (Munich, DE)

Tuesday, March 31, 200917:30 - 19:00

Physicians Poster Session

Infectious complications

Tuesday, March 31, 2009
17:30 - 19:00